Given PRSS56 was greatly overexpressed in GC and CRC, we herein selected a gastric cancer cell line AGS and a colorectal cancer cell line HCT116 for DNA methyltransferase inhibitor treatment (Fig. 3a, b). Here, PRSS56 is linked to colorectal carcinoma.